113 related articles for article (PubMed ID: 26626406)
1. Metastatic Group 3 Medulloblastoma in a Patient With Tuberous Sclerosis Complex: Case Description and Molecular Characterization of the Tumor.
Moavero R; Folgiero V; Carai A; Miele E; Ferretti E; Po A; Diomedi Camassei F; Lepri FR; Vigevano F; Curatolo P; Valeriani M; Colafati GS; Locatelli F; Tornesello A; Mastronuzzi A
Pediatr Blood Cancer; 2016 Apr; 63(4):719-22. PubMed ID: 26626406
[TBL] [Abstract][Full Text] [Related]
2. PI3K/mTOR signaling pathways in medulloblastoma.
Mohan AL; Friedman MD; Ormond DR; Tobias M; Murali R; Jhanwar-Uniyal M
Anticancer Res; 2012 Aug; 32(8):3141-6. PubMed ID: 22843885
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
4. Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization.
Bhatia B; Northcott PA; Hambardzumyan D; Govindarajan B; Brat DJ; Arbiser JL; Holland EC; Taylor MD; Kenney AM
Cancer Res; 2009 Sep; 69(18):7224-34. PubMed ID: 19738049
[TBL] [Abstract][Full Text] [Related]
5. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
[TBL] [Abstract][Full Text] [Related]
6. Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities.
Kotulska K; Larysz-Brysz M; Grajkowska W; Jóźwiak J; Włodarski P; Sahin M; Lewin-Kowalik J; Domańska-Pakieła D; Jóźwiak S
Pediatr Dev Pathol; 2009; 12(2):89-95. PubMed ID: 17990907
[TBL] [Abstract][Full Text] [Related]
7. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
Kenerson H; Dundon TA; Yeung RS
Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109
[TBL] [Abstract][Full Text] [Related]
8. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
9. A reliable cell-based assay for testing unclassified TSC2 gene variants.
Coevoets R; Arican S; Hoogeveen-Westerveld M; Simons E; van den Ouweland A; Halley D; Nellist M
Eur J Hum Genet; 2009 Mar; 17(3):301-10. PubMed ID: 18854862
[TBL] [Abstract][Full Text] [Related]
10. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.
Hoogeveen-Westerveld M; Ekong R; Povey S; Mayer K; Lannoy N; Elmslie F; Bebin M; Dies K; Thompson C; Sparagana SP; Davies P; van Eeghen AM; Thiele EA; van den Ouweland A; Halley D; Nellist M
Hum Mutat; 2013 Jan; 34(1):167-75. PubMed ID: 22903760
[TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin and tuberous sclerosis complex.
Wataya-Kaneda M
J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
[TBL] [Abstract][Full Text] [Related]
12. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
13. Tuberous sclerosis complex.
DiMario FJ; Sahin M; Ebrahimi-Fakhari D
Pediatr Clin North Am; 2015 Jun; 62(3):633-48. PubMed ID: 26022167
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic targeting of mTOR in tuberous sclerosis.
Sampson JR
Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the TSC2 gene in human medulloblastoma.
Przkora R; Meyer-Puttlitz B; Schmitt O; Berthold F; Nöthen M; Krauss J; Tonn JC; von Deimling A; Wiestler OD; Pietsch T
Acta Neuropathol; 2001 Oct; 102(4):380-4. PubMed ID: 11603814
[TBL] [Abstract][Full Text] [Related]
16. [Autism, epilepsy and tuberous sclerosis complex: a functional model linked to mTOR pathway].
García-Peñas JJ; Carreras-Sááez I
Rev Neurol; 2013 Feb; 56 Suppl 1():S153-61. PubMed ID: 23446718
[TBL] [Abstract][Full Text] [Related]
17. Evolving neurobiology of tuberous sclerosis complex.
Crino PB
Acta Neuropathol; 2013 Mar; 125(3):317-32. PubMed ID: 23386324
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
[TBL] [Abstract][Full Text] [Related]
19. Congenital segmental lymphedema in tuberous sclerosis complex with associated subependymal giant cell astrocytomas treated with Mammalian target of rapamycin inhibitors.
Prato G; Mancardi MM; Baglietto MG; Janis S; Vercellino N; Rossi A; Consales A; Raso A; Garrè ML
J Child Neurol; 2014 Sep; 29(9):NP54-7. PubMed ID: 24056156
[TBL] [Abstract][Full Text] [Related]
20. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
Astrinidis A; Henske EP
Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
